Raúl Martín-Ruiz

Raúl oversees and coordinates the identification and evaluation of investment opportunities from the scientific and business perspectives.

Raúl serves on the board of CorWave, Anaconda Biomed and MedLumics. Formerly he was board member at STAT-Dx (acquired by Qiagen) and Prexton Therapeutics (acquired by Lundbeck).

Prior to joining Ysios in 2008, he developed his career in Laboratorios Almirall initially in corporate business development (Licensing In and Licensing Out) and then as responsible for developing and managing the business of the company in the Americas and Africa through licensees and distributors.

Initially he was trained as a researcher in the areas of Central Nervous System pharmacology in the Department of Pharmacology of the UPV-EHU (University of the Basque Country), and in neurochemistry in the Department of Neurochemistry of the IIBB-CSIC (Institute for Biomedical Research of Barcelona-Spanish National Research Council).

He holds a bachelor’s degree in Biological Sciences by the UPV-EHU and a Ph.D. in Neurosciences by the same university and the CSIC.